Cara Therapeutics Inc (NASDAQ:CARA) was congratulated by EnterisBioPharma for their successful Phase 2B clinical trial run of its oral formulation CR845, which was designed to aid in the diminishment of pain caused from osteoarthritis.
How The Phase 2B Trial Worked For The Oral Formulation CR845
A Phase 2 Clinical Manufacturing Service Agreement was made between Cara Therapeutics and EnterisBioPharm, this agreement allowed Cara to make use of Peptelligence technology so as to enable the active ingredient to be delivered orally; whereas without this, the only administration would have to be done through I.V drips.
330 patients who suffer from high levels of pain due to osteoarthritiswere used during this trial. The trial randomizes the strength of the pills amongst the patients that are participants of the trial. The three separate tablets of CR845 measures a strength rating of 1.0 mg, 2.5 mg, and 5.0 mg.
This trial takes place over an 8-week period. There are two endpoints that are measured during the trial namely, the primary effectiveness endpoint, which is equivalent to the change from the baseline at the 8th week, in accordance to that of the average weekly data gathered from the daily pain intensity score, using a numerical rating system.
As well as, the secondary endpoint, which for this phase, extends to change that occurs from the baseline in the Western Ontario and McMaster Osteoarthritis Index (WOMAC), the amount of medication used, as well as the patient global impression of change (PGIC)
Executive Remarks On The Succession Of The Trial
The Chief Executive Officer, and Executive Chairman of EnterisBioPharma; Joel Tune stated that EnterisBioPharma congratulated Cara Therapeutics on the successful results of the Phase 2B clinical trial. Furthermore, Tune went on to state that he believes the success of this trial represents the safety, and competence of their oral drug delivery platform; Peptelligence.
In response to this statement, the CEO of Cara Therapeutics, Derek Chalmers remarked that the ability to orally deliver CR845 provides a large market opportunity for Cara in respect to the treatment of both chronic and acute pain.
Furthermore, Chalmers stated that the company is impressed with the propriety oral delivery technology supplied by Enteris and welcomes assistance into the development of CR845.